|
|
Volumn 302, Issue 6, 2009, Pages 616-618
|
|
Lung cancer trials probe effects of maintenance therapy, targeted agents
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CISPLATIN;
DOCETAXEL;
ERLOTINIB;
PEMETREXED;
PLACEBO;
THYMIDYLATE SYNTHASE;
VANDETANIB;
ANTINEOPLASTIC AGENT;
DRUG DERIVATIVE;
GLUTAMIC ACID DERIVATIVE;
GUANINE;
MONOCLONAL ANTIBODY;
N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE;
N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE;
PIPERIDINE DERIVATIVE;
QUINAZOLINE DERIVATIVE;
TUMOR MARKER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG EFFECT;
DRUG INHIBITION;
DRUG SENSITIVITY;
DRUG TARGETING;
DRUG TOLERABILITY;
HISTOLOGY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MAINTENANCE THERAPY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SHORT SURVEY;
LUNG TUMOR;
METABOLISM;
MORTALITY;
NOTE;
PATHOLOGY;
SURVIVAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
GLUTAMATES;
GUANINE;
HUMANS;
LUNG NEOPLASMS;
PIPERIDINES;
QUINAZOLINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SURVIVAL ANALYSIS;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 68849123063
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2009.1118 Document Type: Short Survey |
|
Times cited : (3)
|
|
References (0)
|